Syndax Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report covers the results of the Annual Meeting of Stockholders held by Syndax Pharmaceuticals, Inc. on May 13, 2021. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Both nominees were elected to serve three-year terms until the 2024 Annual Meeting.
- Jennifer Jarrett: 27,204,848 votes For; 14,005,523 votes Withheld; 3,712,252 Broker Non-Votes.
- William Meury: 31,325,855 votes For; 9,884,516 votes Withheld; 3,712,252 Broker Non-Votes.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
- Votes For: 44,906,957
- Votes Against: 15,362
- Abstain: 304
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management commentary on future outlook, specific risks, contingencies, or unusual items. Detailed descriptions of the proposals are referenced in the definitive proxy statement filed on April 1, 2021.
Key Facts for Investor Verification
- Both director nominees (Jennifer Jarrett and William Meury) were successfully elected.
- Deloitte & Touche LLP was ratified as the independent auditor for the 2021 fiscal year.
- There were significant broker non-votes (3,712,252) recorded for the director election proposals.
- Review the definitive proxy statement filed on April 1, 2021, for detailed background on the nominees and auditor selection.